How Cerebrolysin works
An injectable pig brain mixture with mixed stroke, brain-injury and dementia evidence.
Also called: FPF-1070, Cerebrolysin concentrate.
Nootropic peptides · Porcine brain-derived peptide and amino-acid mixture · Evidence: Approved drug.
The mixture may change how injured nerve cells survive and rebuild connections. Most explanations come from lab work. Its active ingredients and effects in humans are not fully mapped; it is not a measured dose of BDNF or other named growth factors.
- Nerve-cell survival and connections: Growth-supporting effects in lab systems; no single proven human receptor target.
- Peptide mixture: One online sample contained 638 peptides, mostly fragments of structural proteins.
Half-life: Unknown for the mixture; no validated single human half-life.
Related to Cerebrolysin
- Semax: A Russian nasal peptide with limited human evidence for brain and nerve effects.
- Selank: A Russian nasal anxiety peptide with uncertain long-term benefit and safety.
- PE-22-28: An experimental mood peptide studied in mice, with no human trials found.
- Dihexa: An experimental memory compound with disputed animal research and no established human dose.
- P21: An experimental memory peptide with animal research and no established human dose or safety profile.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke., Beghi E et al. · European journal of neurology · 2021
- Tailor Made Compounding LLC - 594743 - 04/01/2020, FDA · FDA · 2020
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
- CEREBROLYSIN, BASG
- Drug Product Database online query, Health Canada
- PHARMACY & POISONS BOARD OF HONG KONG | 香港藥劑業及毒藥管理局, Hong Kong Department of Health
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.